Cogent Biosciences shares are trading higher after the company announced that the FDA approved its new drug application for bezuclastinib in patients with nonAdvanced systemic mastocytosis.

Benzinga Newsdesk www.benzinga.com Positive 95.1%

Neg 0% Neu 0% Pos 95.1%

Comments

No comments yet. Be the first!